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A b s t r a c t
Background: The rate of significant conduction disturbances requiring permanent pacemaker implantation (PPI) following
surgical aortic valve replacement (AVR) is 2–8%. Transcatheter aortic valve implantation (TAVI) is an alternative management
approach in patients with severe aortic stenosis who are not considered candidates for AVR. The TAVI using the CoreValve
(CV) bioprosthesis is associated with a nearly 30% rate of conduction disturbances requiring postprocedural PPI.
Aim: To provide an initial evaluation of the rate of conduction disturbances and the need for PPI, and to analyse factors that
increase the risk of this complication in patients undergoing TAVI using CV bioprosthesis. In addition, we evaluated the rate
of permanent conduction disturbances in patients who underwent PPI at one year after TAVI.
Methods: We studies 22 initial patients in a single centre who underwent CV bioprosthesis implantation in 2009–2010. After
exclusion of 6 patients with preprocedural PPI, we ultimately evaluated 16 patients. Uni- and multivariate analyses were per-
formed using c2, Fisher, and Wilcoxon tests, and logistic regression analysis was performed using the SAS software.
Results: Overall, 8 (50%) patients in our study group required PPI after TAVI (TAVI + PPI), and the remaining 8 patients did
not require PPI (TAVI). The most common indication for PPI was complete heart block. The decision to implant a pacemaker
was made on average at 9 ± 7 days following TAVI (range 3 to 22 days). When we analysed risk factors for PPI that were
unrelated to the TAVI procedure, we found that the TAVI + PPI group was characterised (vs the TAVI group) by a significantly
larger diameter of the native aortic valve (p = 0.03) and a larger left ventricular outflow tract (LVOT) dimension in the frontal
(p = 0.02) and the corresponding frontal dimension in the transverse view (p = 0.01) by computed tomography angiography.
Logistic regression analysis showed that the risk of PPI increased more than 2.5 times for each increase in the aortic annulus
diameter by 1 mm (OR 2.64; 95% CI 0.90–7.74). None of the risk factors related to TAVI resulted in a significant increase in
the rate of PPI. Among the patients who underwent PPI, we only noted a trend for a larger valvulotomy balloon diameter
(p = 0.08), shorter procedure duration (p = 0.06), and deeper CV insertion within LVOT (p = 0.09). In addition, the biopros-
thesis was inserted deeper in those patients who developed new LBBB after TAVI (p = 0.06). The ECG analysis at one day after
the procedure showed a significant prolongation of PR, QRS, QT, and QTc intervals, and increased left axis deviation in the TAVI +
+ PPI group. In addition, the TAVI + PPI group showed increased QRS duration (p = 0.03) and increased left axis deviation
(p = 0.049) compared to the TAVI group. Each increase in QRS duration by 10 ms was associated with 2.5-fold increase in the
risk of PPI (OR 1.10; 95% CI 0.97–1.22), and each increase in PR interval duration by 10 ms with a 23% increase in risk (OR 1.02;
95% CI 0.99–1.05). New LBBB following CV implantation was noted significantly more frequently in the TAVI + PPI group vs
the TAVI group (p < 0.0003). Pacemaker interrogation at one year after TAVI showed that the mean percentage of ventricular
pacing in all patients with a pacemaker (DDD and VVI) pacing was 41%, and it was less than 10% in 2 patients.
Conclusions: 1. Transcatheter implantation of a CV bioprosthesis is associated with an increased risk of persistent conduction
disturbances and subsequent PPI. 2. New LBBB after TAVI may predict the need for PPI. 3. Careful ECG monitoring is necessary for
one week after CV bioprosthesis implantation due to a risk of atrioventricular conduction disturbances and the need for PPI.
4. Patients at an increased risk of postprocedural PPI may be those with deep bioprosthesis insertion in LVOT, larger LVOT diam-
eter, and larger aortic annulus diameter in the frontal view. These observations require confirmation in a larger group of patients.
Key words: aortic stenosis, TAVI, CoreValve bioprosthesis, conduction disturbances, permanent cardiac pacing
Kardiol Pol 2012; 70, 2: 121–128
122
www.kardiologiapolska.pl
Katarzyna Czerwińska et al.
INTRODUCTION
Degenerative aortic stenosis (AS) with calcifications is well
known to be associated with cardiac conduction disturban-
ces. Specifically, electrophysiological studies revealed that
patients with severe AS are prone to prolongation of atrio-
ventricular (AV) nodal conduction and nodoventricular con-
duction [1]. The rate of cardiac conduction disturbances in
patients after conventional aortic valve replacement (AVR) is
estimated at nearly 33%, and the rate of intermittent comple-
te heart block may be up to 17% [1–3]. Permanent pacema-
ker implantation (PPI) following AVR is necessary in 3 to 8%
of cases [1–4]. Cardiac conduction disturbances are associa-
ted with an increased risk of adverse cardiovascular events in
the postoperative period [3]. Occurrence of AV conduction
disturbances after AVR may be readily explained by anatomi-
cal proximity of the cardiac conduction system and aortic
valve structures. The proposed aetiology includes calcifica-
tions, mechanical damage, and ischemia of the cardiac con-
duction system during the surgery [4, 5]. Established risk fac-
tors for PPI in patients undergoing AVR include female gen-
der, impaired left ventricular systolic function, arterial and
pulmonary hypertension, bileaflet aortic valve, concomitant
aortic regurgitation, and bundle branch blocks [1, 2, 4, 5].
Koplan et al. [5] showed that right bundle branch block (RBBB)
was the strongest predictor of pacemaker dependency after
AVR [1, 6].
Transcatheter aortic valve implantation (TAVI) is an alter-
native management approach in patients with severe AS in
whom conventional AVR cannot be performed or is associa-
ted with an unacceptably high risk of perioperative mortality.
By avoiding sternotomy and cardiopulmonary bypass, this new
approach has reduced the perioperative complication rate, in-
cluding mortality, in the elderly patients compared to conven-
tional AVR [6–8]. Results of studies to evaluate effectiveness
and safety of this new treatment are encouraging (PARTNER,
SOURCE) [9, 10]. It is of concern, however, that these procedu-
res are associated with a high incidence of conduction distur-
bances requiring PPI in the postprocedural period, particularly
with the use of CoreValve (CV) bioprosthesis [1–4, 6, 11–14]. In
contrast to AVR, calcifications associated with the aortic valve
are not removed during TAVI, and thus is has been speculated
that a heavily calcified native valve compressed by the expan-
ded bioprosthesis damages the conduction system in the area
of the membranous part of the ventricular septum [6, 13]. In
addition, a longer CV bioprosthesis stent, which is inserted
relatively deeply into the left ventricular outflow tract (LVOT),
is probably responsible for a greater rate of postprocedural
PPI compared to Edwards-Sapien and Sapien XT (ES) valves
(20–30% vs 5–6%) [2, 3, 6, 12, 13].
The aim of the study was to provide an initial evaluation of
the rate of conduction disturbances and the need for PPI, and
to analyse factors that increase the risk of this complication in
patients undergoing TAVI using CV bioprosthesis. In addition,
we evaluated the rate of permanent conduction disturbances
in patients who underwent PPI at one year after TAVI.
METHODS
We studied 22 initial patients who underwent CV bioprosthesis
implantation in the Institute of Cardiology in Warsaw betwe-
en January 2009 and December 2010. Six patients, in whom
PPI was performed before TAVI, were excluded from this
analysis, and thus we ultimately evaluated 16 patients, inclu-
ding 8 (50%) who required PPI after TAVI.
In all patients, electrocardiography (ECG) was performed
within 24 h before TAVI. The procedure was performed un-
der general anaesthesia or sedation under ECG control. Bio-
prosthesis implantation was always preceded by aortic valvu-
loplasty performed during rapid right ventricular pacing (160–
–200 bpm). Mean balloon size was adjusted to the aortic an-
nulus diameter. A CV bioprosthesis was implanted during the
baseline cardiac rhythm of the patient. A transvenous pacing
lead was temporarily left in the right ventricular cavity for 48 h
after the procedure to protect from possible cardiac conduc-
tion disturbances. Postprocedural ECG was performed direc-
tly upon return of the patient to the cardiac care unit and
subsequently daily. The ECG parameters were measured elec-
tronically. Indications for PPI included complete heart block,
persistent advanced AV blok, temporary bifascicular block
with bradycardia, alternating bundle branch block with bra-
dycardia, and symptomatic bradycardia.
The diameter of the native aortic valve annulus was esti-
mated by transoesophageal echocardiography, depth of bio-
prosthesis insertion into LVOT was measured in angiographic
images immediately after bioprosthesis implantation. In all
cases, distances between the floor of the right and left coro-
nary sinuses and the proximal margin of the bioprosthesis were
measured and averaged.
The LVOT diameter was evaluated using 64-row multi-
detector computed tomography images acquired routinely
during patient selection for the procedure. In all cased, LVOT
diameter was measured 6 mm below the aortic annular pla-
ne in frontal, sagittal and transverse views (Figs. 1, 2).
Coronary angiography was performed routinely during
patient selection for the procedure, within 6 months before
TAVI. If coronary angioplasty and stenting were necessary, the-
se procedures had to be performed within 4 weeks before TAVI.
Uni- and multivariate analyses were performed using c2,
Fisher, and Wilcoxon tests, and logistic regression analysis was
performed using the SAS software.
RESULTS
Eight (50%) patients in the analysed population required PPI
after TAVI. Overall, mortality among the 22 patients was 13.63%
(3 patients): one patient died due to a haemorrhagic complica-
tion on the first day after the procedure, another patient died
after many days of hospitalisation due to decompensated he-
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art failure, and the third patient, who required valve in valve
implantation, died two months after hospital discharge, and
the cause of death has not been clearly established.
Sinus rhythm was present before the procedure in 81.25%
of patient, and permanent atrial fibrillation (AF) was found in
the remaining patients. Table 1 shows characteristics of the
study group.
Risk factors for permanent pacing
Risk factors for permanent pacing that were unrelated to the
procedure are shown in Table 2. Patient who underwent CV
bioprosthesis implantation followed by PPI (TAVI + PPI gro-
up) were older than patients who did not require PPI (TAVI
group) but this difference in age was not significant. Mean
estimated surgical risk was insignificantly higher in the TAVI
+ PPI group. Of the analysed anatomical parameters, LVOT
diameter in the TAVI + PPI group was significantly greater in
two of the four evaluated computed tomography angiogra-
phy views: frontal (LVOT1; p = 0.02) and the corresponding
frontal dimension in transverse view (LVOT3; p = 0.01). The
diameter of the native aortic annulus measured in the frontal
view was also higher in the TAVI + PPI group (p = 0.03). In
multivariate analysis, the risk of PPI increased more than
Figure 1. Computed tomography angiography, left ventricular
outflow tract diameter measured 6 mm below the aortic
annulus plane in the frontal view
Table 1. Characteristics of 22 patients who underwent CoreValve
bioprosthesis implantation
Bioprostheses: CV 29 mm/CV 26 mm 14 (63.63%)/8 (36.36%)
Implantation route: TF/Tsc. 19 (86.36%/3 (13.63%)
EuroSCORE [%] 26.33 ± 14.48
Age [years]: 80.27 ± 7.19
≥ 75 20 (90.9%)
Body mass index [kg/m2] 26.37 ± 4.09
Female gender 13 (59.09%)
Left ventricular dysfunction:
EF £ 50% 11 (50%)
EF £ 35% 5 (22.72%)




Chronic obstructive pulmonary disease 8 (36.36%)
Porcelain aorta 1 (4.55%)
Advanced osteoporosis 3 (13.64%)
Renal failure (creatinine level ≥ 200 mmol/L; 15 (68.18%)
GFR < 60 mL/min/1.73 m2)
Coronary artery disease 19 (86.36%)
Previous CABG 4 (18.18%)
Previous PTCA 7 (31.82%)
Previous myocardial infarction 5 (22.73%)
Arterial hypertension 18 (81.82%)
Pulmonary hypertension 12 (54.55%)
Diabetes type 2 11 (50%)
History of stroke/TIA 5 (22.73%)
History of anaemia 12 (54.55%)
Duration of hospital stay [days] 18.95 ± 13.77
EF — ejection fraction; TF — transfemoral; Tsc. — transsubclavian;
CABG — coronary artery bypass grafting; PTCA — percutaneous
transluminal coronary angioplasty; TIA — transient ischaemic attack
Figure 2. Computed tomography angiography, left ventricular
outflow tract diameter measured 6 mm below the aortic annulus
plane in the transverse view (frontal and sagittal dimensions)
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2.5 times for each increase in the aortic annulus diameter by
1 mm (OR 2.64; 95% CI 0.90–7.74).
Risk factors for PPI related to TAVI are shown in Table 3.
In the TAVI + PPI group, a 29 mm bioprosthesis was implan-
ted in 7 patients, and a 26 mm bioprosthesis in one patient.
In the TAVI group, a 26 mm bioprosthesis was implanted in
4 patients, and a 29 mm bioprosthesis in 4 patients. The diffe-
rence in bioprosthesis size had no significant effect on whether
PPI was needed. None of the analysed potential risk factors
related to the procedure significantly affected the need for
PPI. Among the patients who underwent PPI, we only noted
a trend for a larger valvulotomy balloon diameter (p = 0.08),
shorter procedure duration (p = 0.06), and deeper CV inser-
tion within LVOT (p = 0.09). In addition, when assessing the
depth of bioprosthesis insertion within LVOT, we analysed
whether it was related to the occurrence of left bundle branch
block (LBBB) after the procedure. We found that the biopro-
sthesis was inserted deeper in those patients who developed
new LBBB after TAVI (p = 0.06). Differences in the analysed
parameters were not significant, likely due to a low number of
the studied subjects.
ECG analysis
The ECG parameters obtained in the two groups before and
on the first day after the procedure are shown in Table 4. No
significant differences in baseline parameters were seen be-
tween the groups.
Comparison of ECG parameters on the first day after the pro-
cedure showed significantly increased QRS duration (p = 0.03)
and left axis deviation (p = 0.049) in the TAVI + PPI group
compared to the TAVI group (Table 4). In the TAVI group, CV
bioprosthesis implantation was associated with significant left
axis deviation (p = 0.01; significantly more commonly in those
patients who underwent PPI) and prolongation of corrected QT
(QTc) interval (p = 0.01). In the TAVI + PPI group, all ECG para-
meters increased significantly on the first day after the proce-
Table 2. Risk factors for permanent pacemaker implantation unrelated to TAVI
Risk factor TAVI TAVI + PPI P
Age [years] 77.12 ± 9.99 80.25 ± 3.53 0.6
EuroSCORE [%] 15.79 ± 6.58 24.33 ± 9.78 0.07
LVOT1 [mm] 26.50 ± 2.20 29.12 ± 1.24 0.02
LVOT2 [mm] 20.00 ± 2.07 20.87 ± 1.55 0.46
LVOT3 [mm] 25.87 ± 2.79 30.5 ± 1.85 0.01
LVOT4 [mm] 22.37 ± 4.40 22.0 ± 1.51 0.95
Aortic annulus [mm] 22.75 ± 1.16 24.37 ± 1.59 0.03
Coronary artery disease 6/8 (75%) 8/8 (100%)] 0.07
Previous myocardial infarction 3/8 (37.5%) 1/8 (12.5%) 0.23
Diabetes type 2 4/8 (50%) 5/8 (62.5%) 0.51
Heart failure 4/8 (50%) 4/8 (50%) 1.0
Pulmonary hypertension 4/8 (50%) 6/8 (75%) 0.29
LVOT1 — left ventricular outflow tract width in the frontal view by computed tomography (CT) angiography; LVOT2 — LVOT width in the sagittal view
by CT angiography; LVOT3 — LVOT width, frontal dimension in the transverse view by CT angiography; LVOT4 — LVOT width, sagittal dimension in
the transverse view by CT angiography
Table 3. Risk factors for permanent pacemaker implantation directly related to TAVI
Risk factor TAVI TAVI + PPI P
Bioprosthesis diameter [mm] 27.5 ± 1.6 28.62 ± 1.06 0.15
Balloon [mm] 23.5 ± 1.6 25.0 ± 1.6 0.08
Duration of the procedure: 183.57 ± 49.47 136.42 ± 37.04 0.06
D valve/annulus [mm] 4.75 ± 1.48 4.25 ± 1.58 0.56
D balloon/annulus [mm] 0.75 ± 1.48 0.62 ± 2.26 0.71
Mean CoreValve depth within LVOT [cm] 5.39 ± 2.69 9.70 ± 4.74 0.09
TF/Tsc. 6/8 (75%) 7/8 (87.5%) 1.0
Mean CoreValve depth within LVOT in patients with new LBBB [cm] 5.38 ± 2.38 9.7 ± 4.73 0.06
LVOT — left ventricular outflow tract; TF — transfemoral route; Tsc. — transsubclavian route; LBBB — left bundle branch block
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dure, including PQ (p = 0.01), QRS (p = 0.01), QT (p = 0.04),
and QTc (p = 0.01) intervals, and left axis deviation (p = 0.04).
We found that each increase in QRS duration by 10 ms was
associated with 2.5-fold increase in the risk of PPI (OR 1.10;
95% CI 0.97–1.22), and each increase in PR interval duration
by 10 ms with a 23% increase in the risk of PPI (OR 1.02; 95%
CI 0.99–1.05) in the study group.
Before the procedure, no difference in the prevalence of
LBBB was noted between the groups. Bundle branch blocks
related to the procedure developed within minutes to hours
after bioprosthesis implantation. New LBBB after CV biopro-
sthesis implantation was significantly more common in those
patients who subsequently required PPI (it occurred in all
patients in this group; p £ 0.0001) (Table 5). The most com-
mon indication for PPI was complete heart block which de-
veloped in 5 patients within several hours to 3 days after the
procedure. In addition, in one patient with complete heart
block on the third day after the procedure, successfully resu-
scitated cardiac arrest occurred previously during CV biopro-
sthesis implantation. Among patients in the TAVI group, one
case of advanced AV block with intermittent complete heart
block was diagnosed. For this reason, temporary pacing was
used for the first two days after the procedure but the block
turned out to be short-term and self-limiting. In the TAVI +
+ PPI group, advanced AV block was an indication for PPI in
two patients. Symptomatic bradycardia was an indication for
PPI in one patient in whom the procedure was associated
with a first-in-life AF episode with alternating bundle branch
blocks and symptomatic bradycardia.
Follow-up pacemaker interrogation
Eight permanent pacemakers were implanted, including 7 AV
pacemakers and one ventricular pacemaker. The decision to
implant a pacemaker was made on average at 9 ± 7 days
following TAVI (range 3 to 22 days). Pacemaker interrogation
at one year after TAVI showed that the mean percentage of
ventricular pacing in all patients with a pacemaker (DDD and
VVI) pacing was 41%, and it was less than 10% in 2 patients.
In the only patient with a ventricular pacemaker, percentage
of ventricular pacing at the basic rate of 70 bpm was 85%. In
5 patients with AV pacemakers, Auto Mode Switch episodes
(automatic switch from DDD to DDI pacing with the occur-
rence of supraventricular arrhythmia) were detected, most li-
kely due to AF episodes, although this arrhythmia was not
seen before bioprosthesis implantation in any of the patients.
The analysed parameters are summarised in Table 6.
DISCUSSION
Anatomical proximity of the aortic valve complex to the AV
node, His bundle and its branches may explain the observed
increase in conduction disturbances after TAVI [12, 13]. The
depth of insertion of the proximal end of CV bioprosthesis
stent seems to be the major aetiologic factor of new LBBB
following the procedure, and the occurrence of the latter wi-
thin several hours after bioprosthesis implantation precedes
the need for PPI [11–13]. A high incidence of new LBBB sug-
gests that previously diagnosed RBBB should be considered
a risk factor for complete heart block and such patients requ-
ire careful monitoring [12, 13].
Table 4. ECG parameters in TAVI and TAVI + PPI groups before and on the first day after TAVI
PQ [ms] QRS [ms] QT [ms] QTc [ms] Electrical axis [°] HR [bpm]
ECG parameters in TAVI and TAVI + PPI groups on the day before TAVI
TAVI 178.85 ± 38.46 107.5 ± 20.21 424.25 ± 39.76 435.62 ± 13.89 13.25 ± 34.96 68.12 ± 21.41
TAVI + PPI 180.85 ± 33.68 112.0 ± 33.96 431.75 ± 33.42 427.75 ± 54.74 4.42 ± 39.26 64.28 ± 8.03
P 0.53 0.95 0.53 0.41 0.77 0.86
ECG parameters in TAVI and TAVI + PPI groups on the first day after TAVI
TAVI 173.57 ± 37.91 122.0 ± 29.81 439.12 ± 50.40 492.25 ± 61.06 –4.75 ± 32.48 78.87 ± 13.97
TAVI + PPI 210.5 ± 39.56 158.0 ± 11.22 463.37 ± 44.89 496.87 ± 37.47 –35.75 ± 24.17 70.62 ± 11.46
P 0.11 0.03 0.38 1.0 0.049 0.5
PPI — permanent pacemaker implantation; TAVI —  transcatheter aortic valve implantation; HR — heart rate
Table 5. Complete heart block after TAVI and left bundle branch block before and after TAVI in TAVI and TAVI + PPI groups
Group Complete heart block after TAVI LBBB before TAVI LBBB after TAVI u P
TAVI 1/8 (12.5%) 0/8 (0%) 3/8 (37.5%) 2.64 0.008
TAVI + PPI 5/8 (62.5%) 1/8 (12.5%) 8/8 (100%) 4.84 < 0.0001
u 2.20 1.45 3.65
P < 0.03 0.15 < 0.0003
PPI — permanent pacemaker implantation; TAVI —  transcatheter aortic valve implantation; LBBB — left bundle branch block
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Koplan et al. [5] analysed baseline ECG parameters in
patients undergoing AVR and found that LBBB, RBBB, and
first degree AV block are independent risk factors for post-
procedural need for PPI, and RBBB diagnosed before AVR
was the strongest predictor of PPI. This is related to more
frequent damage of the left bundle branch during AVR or
mitral valve replacement, which results in complete heart
block when combined with preexisting RBBB. Similar conc-
lusions were drawn by Piazza et al. [1] who analysed compli-
cations related to TAVI.
Khawaja et al. [13] analysed 243 patients from 10 cen-
tres in the United Kingdom and identified the following risk
factors of conduction disturbances requiring PPI after TAVI:
AV block, LBBB, RBBB, and preprocedural QRS widening.
Predictors of postprocedural high-degree AV block included
preprocedural PR interval prolongation, QRS widening, and
the degree of left axis deviation.
Observed conduction disturbances may partially result
from inflammation and repair processes within ventricular
septal myocardium adjacent to the bioprosthesis stent [3, 11].
This is confirmed by regression of prolonged PR and QRS
intervals seen in subsequent days after TAVI [2]. Compared
to the literature data, we observed a high rate of early post-
procedural PPI (50%). This discrepancy is likely related to
a small number of patients in our study and required further
studies. Our findings do not confirm previous suggestions [1–6,
11–13] that preprocedural RBBB is a risk factor for PPI follo-
wing CV bioprosthesis implantation. We were also unable to
identify other arrhythmias and conduction disturbances oc-
curring before TAVI that would be associated with a subse-
quent need for permanent pacing. We found, however, that
CV bioprosthesis implantation induces changes in the car-
diac conduction system already in the first postprocedural
day, as indicated by a significant increase in the rate of new
LBBB after the procedure in both study groups.
The American National Heart, Lung, and Blood Institute
Balloon Valvuloplasty Registry of 1991 and a 2002 study re-
ported the need for PPI in 4% and 3.5% patients undergoing
aortic valve valvulotomy, respectively. Mechanical and ischa-
emic damage related to prior valvulotomy, the use of a larger
bioprosthesis (29 mm), and a mismatch between bioprosthe-
sis size and aortic annulus diameter are established risk factors
for PPI [12, 13]. Similarly, our findings show a trend for worse
outcomes regarding postprocedural PPI with the use of larger
predilatation balloons and larger bioprostheses, and deeper bio-
prosthesis insertion within LVOT. When we assessed changes
in ECG parameters in the 16 patients included in the present
analysis, significant QRS widening was noted on the first post-
procedural day in all patients, while the TAVI + PPI group was
characterised by a significant increase in all analysed ECG pa-
rameters. Khawaja et al. [13] highlighted the importance of QRS
width as a predictor of PPI and suggested that lack of postpro-
cedural QRS widening and/or new bundle branch block elimi-
nates the need for prolonged ECG monitoring [14].
In a multivariate analysis, Khawaja et al. [13] found that
QRS width after TAVI showed the strongest positive correla-
tion with preprocedural QRS widening and the depth of bio-
prosthesis insertion within LVOT. They also showed that in-
terventricular septal thickness correlated positively with the
need for PPI, and aortic annulus diameter correlated positi-
vely with the occurrence of a high-degree AV block. Thus,
LVOT and native aortic annulus anatomy and width may also
be associated with postprocedural PPI. When we analysed
these parameters, the 8 patients in the TAVI + PPI group
were characterised by a significantly wider LVOT in the fron-
tal view and corresponding transverse view in computed to-
mography angiography, and a significantly larger native aortic
annulus diameter in these views. Native aortic valve and LVOT
dilatation may be considered an indicator of an advanced
disease of the aortic valve complex, and cardiac conduction
system damage may be directly induced by forcible rapid di-
lation of the predilatation balloon and the bioprosthesis wi-
thin a larger aortic valve orifice [2].
Both LVOT and aortic annulus are ellipsoid-shaped struc-
tures in a cross-sectional view. Significantly larger LVOT di-
mensions in the frontal plane in patients in the TAVI + PPI
group may indicate an effect of LVOT asymmetry, i.e. incre-
ased bioprosthesis compression of the cardiac conduction
system within the interventricular septum along the sagittal
dimension, leading to significant postprocedural AV conduc-
tion disturbances [13]. However, reliable interpretation of
these findings is precluded by a small number of patients in
our study.
Overall, PPI following AVR is necessary in 6–6.5% of the
elderly patients [1, 2]. Patients undergoing TAVI are usually
elderly subjects with multiple comorbidities. Recent studies
show that patient age correlates significantly with QRS wide-
ning and the occurrence of high-degree AV blocks [13].
Table 6. Follow-up pacemaker interrogation parameters
Parameter Results
Basic rate [bpm] 65.0 ± 5.5
SAVD [ms] 204.2 ± 31.4
PAVD [ms] 221.7 ± 35.6
Search AV [ms] 66.7 ± 30.8
A pacing [%] 58 ± 22
V pacing [%] 41 ± 39
AVD native [ms] 229.8 ± 61.7
SAVD — programmed atrioventricular (AV) delay for sensed atrial
impulses; PAVD — programmed AV delay for paced atrial impulses;
Search AV — programmed AV delay prolongation to promote native
impulse conduction; A pacing — percentage of atrial pacing; V pacing
— percentage of ventricular pacing; AVD native — native AV conduction
delay (maximum delay between sensed atrial impulse and sensed
ventricular impulse)
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In our analysis, the mean age of patients in the TAVI +
+ PPI group was increased compared to the TAVI group but
this difference did not reach statistical significance. It has been
found, however, that the risk of PPI after TAVI increases by
6.6% with each year of life.
Piazza et al. [1] showed that the depth of bioprosthesis
insertion within LVOT is an aetiologic factor contributing to
conduction disturbances following TAVI [1–6, 11, 12] and
suggested that insertion of the proximal end of CV biopro-
sthesis by < 6.7 mm within LVOT does not result in an incre-
ased risk of PPI. In our study, we only observed a trend for an
increased need for PPI and increased incidence of new LBBB
with deeper bioprosthesis insertion.
An unexpected observation is an inverse association be-
tween the duration of implantation procedure and the risk of
PPI: every increase in TAVI procedure duration by one minu-
te reduced the need for PPI by 2.7%. Evaluation whether it
has been a chance finding will be possible upon examining
a larger group of patients. Regarding appropriateness of the
decision to implant a pacemaker and indications for pacing,
follow-up pacemaker interrogation showed that the percen-
tage of ventricular pacing was less than 10% in 2 patients
which, as suggested by Jilaihawi et al. [11] may indicate an
improvement of native AV conduction or a premature deci-
sion to implant a pacemaker in these patients. In such situ-
ations it is, however, difficult to exclude that appropriate ven-
tricular pacing actually occurs whenever an advanced AV
block develops. Atrioventricular delay for sensed atrial im-
pulses and paced atrial impulses and algorithms promoting
native AV conduction have been programmed so as to redu-
ce the percentage of ventricular pacing. Thus, the reported
percentage of ventricular pacing seems approximate to the
values that are both necessary and safe for the patients. In
addition, the programmed basic rate (60–70 bpm in our pa-
tients) may also affect pacemaker parameters read upon fol-
low-up pacemaker interrogation.
Limitations of the study
One limitation of our study was a small number of the analy-
sed patients. In addition, this was a single-centre experience,
with all procedures performed by the same team. Thus, our
findings should be considered preliminary and require con-
firmation in a larger sample.
CONCLUSIONS
1. Transcatheter implantation of a CV bioprosthesis is asso-
ciated with an increased risk of persistent conduction
disturbances and subsequent PPI.
2. New LBBB after transcatheter CV bioprosthesis implan-
tation may predict the need for PPI.
3. Careful ECG monitoring is necessary for one week after
CV bioprosthesis implantation due to a risk of AV con-
duction disturbances and the need for PPI.
4. Patients at an increased risk of postprocedural PPI may
be those with deep bioprosthesis insertion in LVOT, lar-
ger LVOT diameter, and larger aortic annulus diameter
in the frontal view. These observations require confirma-
tion in a larger group of patients.
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Zaburzenia przewodzenia i stała stymulacja serca
po przezcewnikowej implantacji bioprotezy
aortalnej CoreValve: wstępne doświadczenia
jednego ośrodka
Katarzyna Czerwińska, Tomasz Hryniewiecki, Artur Oręziak, Maciej Dąbrowski, Ilona Michałowska,
Adam Witkowski, Marcin Demkow, Janina Stępińska, Ewa Orłowska−Baranowska, Witold Rużyłło
Instytut Kardiologii, Warszawa
S t r e s z c z e n i e
Wstęp: Odsetek poważnych zaburzeń rytmu i przewodzenia wymagających implantacji układu stymulującego (PPI) po kardiochi-
rurgicznej wymianie zastawki aortalnej (AVR) sięga 2–8%. Przezcewnikowa implantacja zastawki aortalnej (TAVI) stanowi alterna-
tywną metodę leczenia dla chorych z ciasną stenozą aortalną wyłączonych z AVR; TAVI z zastosowaniem bioprotezy CoreValve
(CV) wiąże się z ok. 30-procentowym odsetkiem zaburzeń przewodzenia wymagających PPI w okresie pozabiegowym.
Cel: Celem pracy była wstępna ocena częstości występowania zaburzeń przewodzenia i konieczności PPI oraz analiza czynników
zwiększających ryzyko takiego powikłania u chorych poddawanych przezcewnikowej implantacji CV w ujście aortalne. Ponadto
oszacowano odsetek utrzymujących się zaburzeń przewodzenia u chorych z PPI podczas kontroli urządzenia do roku po TAVI.
Metody: Badaniem objęto 22 pierwszych chorych z jednego ośrodka poddanych implantacji CV w latach 2009–2010. Osta-
tecznej analizie poddano grupę 16 osób po wykluczeniu 6 pacjentów z PPI przed zabiegiem. Analizę statystyczną jedno-
i wieloczynnikową przeprowadzono przy użyciu testu c2, Fishera, Wilcoxona i analizy logistycznej za pomocą systemu SAS.
Wyniki: W badanej grupie 8 (50%) chorych wymagało PPI po TAVI (TAVI + PPI) v. 8 badanych bez konieczności PPI (TAVI).
Blok całkowity był najczęstszą przyczyną kwalifikacji do PPI. Decyzję o implantacji stymulatora podjęto średnio w dobie 9 ± 7
(3–22) po zabiegu. Analizując czynniki ryzyka PPI niezwiązane z zabiegiem, wykazano, że grupę TAVI + PPI v. TAVI charak-
teryzuje istotnie większa średnica pierścienia natywnej zastawki aortalnej (p = 0,03) i szerszy wymiar drogi odpływu lewej
komory (LVOT) w projekcji czołowej (p = 0,02) oraz projekcji poprzecznej (p = 0,01), obliczany na podstawie badania
angio-CT. Analiza logistyczna wykazała ponad 2,5-krotny wzrost ryzyka PPI przy zwiększeniu o 1 mm średnicy pierścienia
aortalnego (OR 2,64; 95% CI 0,90–7,74). Żaden z czynników ryzyka związanych z TAVI nie wpływał istotnie na zwiększenie
odsetka PPI. Natomiast zaobserwowano trend w kierunku większej średnicy balonu do walwulotomii (p = 0,08), krótszego
czasu zabiegu (p = 0,06) i głębszego osadzenia CV w LVOT (p = 0,09) u chorych z PPI. Ponadto proteza była osadzona głębiej
u osób, u których po TAVI rozwinął się nowy blok lewej odnogi pęczka Hisa (LBBB) (p = 0,06). Analiza EKG w 1. dobie po
zabiegu wykazała, że w grupie TAVI + PPI wszystkie oceniane parametry istotnie się wydłużyły: PQ, QRS, QT, QTc i nasiliło
się odchylenie osi elektrycznej serca w lewo. Ponadto grupa TAVI + PPI v. grupa TAVI charakteryzowała się istotnie posze-
rzonymi zespołami QRS (p = 0,03) i większym odchyleniem osi elektrycznej serca w lewo (p = 0,049). Wykazano, że
wydłużenie się czasu trwania QRS o każde 10 ms wiązało się z 2,5-krotnym wzrostem ryzyka (OR 1,10; 95% CI 0,97–1,22),
a wydłużenie się czasu trwania PQ o każde 10 ms z 23-procentowym zwiększeniem ryzyka konieczności PPI (OR 1,02; 95%
CI 0,99–1,05). Nowy LBBB po implantacji CV obserwowano znamiennie częściej w grupie TAVI + PPI v. TAVI (p < 0,0003).
Podczas kontroli układu stymulującego do roku po TAVI odsetek stymulacji komorowej u wszystkich chorych z implantowa-
nym układem stymulującym (DDD i VVI) był równy średnio 41%, a u 2 pacjentów wynosił on mniej niż 10%.
Wnioski: 1. Przezcewnikowa implantacja bioprotezy CV wiąże się ze zwiększonym ryzykiem pojawienia się trwałych zabu-
rzeń przewodzenia i następowej PPI. 2. Nowy LBBB po TAVI może zapowiadać konieczność PPI. 3. Uważna obserwacja
elektrokardiograficzna powinna być prowadzona w ciągu tygodnia po implantacji protezy CV ze względu na możliwość
pojawienia się zaburzeń przewodzenia przedsionkowo-komorowego i konieczność PPI. 4. Wydaje się, że na konieczność
PPI po zabiegu mogą być narażeni chorzy z głębokim osadzeniem protezy w LVOT, większym LVOT i szerszym pierścieniem
aortalnym w wymiarze czołowym. Obserwacja ta wymaga potwierdzenia w większej grupie chorych.
Słowa kluczowe: stenoza aortalna, bioproteza CoreValve, zaburzenia przewodzenia, stała stymulacja serca
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